News for Jaguar Health Stock (JAGX)

Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Accesswire • 09/25/24

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch

Accesswire • 09/24/24

Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference

Accesswire • 09/16/24

Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

Accesswire • 09/10/24

Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference

Accesswire • 09/06/24

Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

Accesswire • 09/05/24

New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company's Near-Term Commercial & Development Milestones

Accesswire • 09/04/24

Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

Accesswire • 08/27/24

Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award

Accesswire • 08/20/24

Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

Accesswire • 08/19/24

Jaguar Health, Inc. (JAGX) Q2 2024 Earnings Call Transcript

Seeking Alpha • 08/13/24

Jaguar Health Reports Second Quarter 2024 Financial Results

Accesswire • 08/13/24

REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial's Clinically Meaningful Results in Breast and Lung Cancer Patients

Accesswire • 08/12/24

Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial's Clinically Meaningful Results

Accesswire • 08/05/24

Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy

Accesswire • 08/02/24

Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting

Accesswire • 08/01/24

Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)

Accesswire • 07/31/24

Jaguar Health, Inc. (JAGX) Special Call Transcript

Seeking Alpha • 07/23/24

Why Is Jaguar Health (JAGX) Stock Down 55% Today?

InvestorPlace • 07/23/24

Jaguar Health's stock slides 68% after cancer trial fails to meet main goal

Market Watch • 07/23/24

Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer

Accesswire • 07/23/24

Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning

Accesswire • 07/18/24

Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement

Accesswire • 06/26/24

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

Accesswire • 06/21/24

Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024

Accesswire • 06/12/24